Karin Jooss
Förmögenhet: 23 537 $ per 2026-08-31
Förmögenhet: 23 537 $ per 2026-08-31
Karin Jooss is currently an Independent Director at Fate Therapeutics, Inc. since 2019.
Former positions include Executive VP & Head-Research & Development at Nexoplex Bio, Inc. from 2021 to 2024, Head-Cancer Immunotherapeutics at Pfizer Inc. from 2009 to 2016, and Vice President-Research at Cell Genesys, Inc. from 2005 to 2009.
Education includes a doctorate from Philipps University of Marburg.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
FATE THERAPEUTICS, INC. 0,01 % | 2026-06-12 | 9 848 ( 0,01 % ) | 23 537 $ | 2026-08-31 |
| Företag | Position | Start |
|---|---|---|
| FATE THERAPEUTICS, INC. | Direktör/Styrelseledamot | 2019-03-14 |
| Företag | Position | Slut |
|---|---|---|
| GRITSTONE BIO, INC. | Teknisk/Vetenskaplig/F&U Direktör | 2024-12-31 |
| PFIZER INC. | Företagsledare/Principal | 2016-04-01 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Develops human disease therapies based on innovative gene modification technologies | Teknisk/Vetenskaplig/F&U Direktör | 2009-04-01 |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 5 |
|---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Develops human disease therapies based on innovative gene modification technologies | Health Technology |
Pfizer Inc.
Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Philipps University of Marburg
Philipps University of Marburg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fate Therapeutics, Inc.
Fate Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
Gritstone bio, Inc.
Gritstone bio, Inc. Pharmaceuticals: MajorHealth Technology Develops immunotherapies for cancer | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån